We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+56.31%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$2.28B
AUM Growth
+$186M
Cap. Flow
+$21.2M
Cap. Flow %
0.93%
Top 10 Hldgs %
55.42%
Holding
67
New
19
Increased
9
Reduced
10
Closed
10

Top Buys

Rank Stock Value
1
CRBP icon
Corbus Pharmaceuticals
CRBP
+$49.9M
2
TRML
Tourmaline Bio
TRML
+$44.1M
3
CGON icon
CG Oncology
CGON
+$32.7M
4
NAMS icon
NewAmsterdam Pharma
NAMS
+$30.4M
5
PRAX icon
Praxis Precision Medicines
PRAX
+$30.4M

Top Sells

Rank Stock Value
1
AMAM
Ambrx Biopharma Inc
AMAM
+$160M
2
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$75.4M
3
IMVT icon
Immunovant
IMVT
+$49.1M
4
CBAY
Cymabay Therapeutics
CBAY
+$42.5M
5
OLMA icon
Olema Pharmaceuticals
OLMA
+$34.5M

Sector Composition

Rank Sector Weight
1 Healthcare 98.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TRML
26
DELISTED
Tourmaline Bio
TRML
$28.6M 1.26%
+1,250,000
New +$44.1M
JANX icon
27
Janux Therapeutics
JANX
$967M
$28.2M 1.24%
+750,000
New +$16.3M
NGNE icon
28
Neurogene
NGNE
$712M
$27.4M 1.2%
538,714
-207,466
-28% -$6.93M
CRGX
29
DELISTED
CARGO Therapeutics
CRGX
$26.4M 1.16%
1,182,563
– –
RYTM icon
30
Rhythm Pharmaceuticals
RYTM
$7.96B
$23.8M 1.05%
550,000
– –
APLS
31
DELISTED
Apellis Pharmaceuticals
APLS
$23.5M 1.03%
400,000
-225,000
-36% -$14.3M
ARQT icon
32
Arcutis Biotherapeutics
ARQT
$3.18B
$21.1M 0.92%
+2,125,000
New +$15.9M
IDYA icon
33
IDEAYA Biosciences
IDYA
$3.56B
$19.7M 0.87%
450,000
– –
CABA icon
34
Cabaletta Bio
CABA
$455M
$18.8M 0.82%
+1,100,000
New +$23.6M
ATXS
35
DELISTED
Astria Therapeutics
ATXS
$18.3M 0.8%
+1,300,000
New +$16.2M
ENGN icon
36
enGene Therapeutics
ENGN
$121M
$16.9M 0.74%
+1,000,000
New +$12.2M
INSM icon
37
Insmed
INSM
$28.6B
$15.6M 0.68%
575,000
– –
VTYX
38
DELISTED
Ventyx Biosciences
VTYX
$14.9M 0.65%
+2,710,000
New +$12.4M
NKTX icon
39
Nkarta
NKTX
$172M
$14.6M 0.64%
+1,350,000
New +$14M
SLN
40
Silence Therapeutics
SLN
$564M
$13.5M 0.59%
+625,000
New +$13.6M
MRSN
41
DELISTED
Mersana Therapeutics
MRSN
$11.6M 0.51%
+104,000
New +$10.3M
CMPX icon
42
Compass Therapeutics
CMPX
$387M
$11M 0.48%
+5,560,300
New +$9.61M
KYTX icon
43
Kyverna Therapeutics
KYTX
$484M
$10.9M 0.48%
+440,000
New +$12.3M
BEAM icon
44
PUT
Beam Therapeutics
BEAM
$2.84B
$9.91M 0.43%
+300,000
New +$9.35M
IMRX icon
45
Immuneering
IMRX
$292M
$9.52M 0.42%
3,295,273
-909,091
-22% -$5.09M
SYRE icon
46
Spyre Therapeutics
SYRE
$9.25B
$9.48M 0.42%
250,000
-687,080
-73% -$19.9M
AVBP icon
47
ArriVent BioPharma
AVBP
$1.44B
$9.2M 0.4%
+515,000
New +$10.4M
RCKT icon
48
Rocket Pharmaceuticals
RCKT
$394M
$8.08M 0.35%
300,000
-150,000
-33% -$4.26M
IRON icon
49
Disc Medicine
IRON
$2.97B
$7.78M 0.34%
125,000
– –
CNTA
50
DELISTED
Centessa Pharmaceuticals
CNTA
$6.35M 0.28%
561,600
– –
1
2
3

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.79% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q1 2024 Portfolio in Review

As of Q1 2024, Cormorant Asset Management held 67 positions worth $2.28B, up 8.9% from $2.09B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Cormorant Asset Management's Q1 2024 filing shows 19 new, 9 increased, 10 reduced and 10 closed positions. Its largest new stake was Corbus Pharmaceuticals: 2,025,000 shares worth $79.5M. The largest sale was Ambrx Biopharma Inc, an estimated $160M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier.

  • Cormorant Asset Management's largest Q1 2024 buy was Corbus Pharmaceuticals: 2,025,000 shares worth $79.5M.
  • Cormorant Asset Management added most to Praxis Precision Medicines in Q1 2024, an estimated $30.4M increase.
  • Cormorant Asset Management's biggest Q1 2024 reduction was Spyre Therapeutics, cutting an estimated $19.9M.
  • Cormorant Asset Management fully exited Ambrx Biopharma Inc in Q1 2024, selling an estimated $160M.
  • Cormorant Asset Management's ten largest holdings make up 55% of its $2.28B portfolio in Q1 2024.
  • Cormorant Asset Management opened 19 new positions and closed 10 in Q1 2024.
  • Cormorant Asset Management's portfolio value rose 8.9% quarter-over-quarter to $2.28B.

Based on Cormorant Asset Management's 13F filing for Q1 2024, filed 15 May 2024.